SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03, Zacks reports. During the same quarter in the previous year, the company earned ($1.34) EPS.

SELLAS Life Sciences Group Stock Down 2.9 %

NASDAQ SLS traded down $0.04 on Friday, hitting $1.18. 200,819 shares of the stock were exchanged, compared to its average volume of 1,410,549. SELLAS Life Sciences Group has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The company has a market cap of $82.70 million, a PE ratio of -1.70 and a beta of 2.43. The company has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.17.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.